Abstract: The invention comprises taking colour pictures of back-lighted analysis microtubes and using the colour information in the images to identify areas of the image which are relevant for interpreting the result of other possible artefacts, as well as detecting abnormal samples and/or reactions characterised by changes in the colour properties of the reaction.

Abstract: Device for taking samples of liquid from a collection container, characterised in that it comprises a support for liquid sample collection containers; a support for a set of containers into which the sample of liquid will be deposited; a support for connection elements; a container handling mechanism; and a device for inserting the containers into which the sample of liquid will be deposited into the connection element.

Abstract: The invention relates to a biocompatible composition which comprises microparticles of alginic acid or its salts and an active ingredient. More particularly, the invention relates to microparticles for the encapsulation of an active ingredient to be administered intravenously to a patient who needs it. These microparticles are of a combination of size sufficient to increase the half-life or survival of the active ingredient in blood, with a low uptake in the liver and a fast cell clearance when administered intravenously.

Abstract: The apparatus comprises a single transportable structure provided with several separate compartments located in a vertical stack within a cabinet, with means for the vertical transport of gel cards, means for the transport of units for moving the cards and pipetting probes, being displaceable to the entire transverse cross-section of the compartments in at least two of the vertical compartments or floors through moving along coordinate axes X, Y, Z at right-angles, and control means so that automatic functioning can take place simultaneously with manual actions to load and unload the necessary materials (samples, reagents, cards, wash solutions and waste solutions) in a random manner.

Abstract: The apparatus comprises an assembly of modules functionally interrelated with one another, and controlled by means of a central control unit in an embodiment of circular type in concentric rings of a reagent module and a rotatory carousel carrying the incubation reaction containers, with adjacent and external arrangement of a module for feeding the disposable reaction containers by means of detachable racks and a scanning device likewise concentric with the carousel, combining with a unit for feeding by pushing the reaction containers from the racks towards the grooves of the incubation carousel, and of two displacement arm devices.

Abstract: A process for purifying and collecting albumin from plasma and plasma fractions involves diafiltration of an albumin-containing plasma fraction; stabilizing the resulting albumin fraction with sodium chloride and an amino acid in the absence of any added fatty acid; pasteurizing the stabilized albumin fraction; and diafiltering the pasteurized fraction to remove, along other things, stabilizers. In one embodiment, the amino acid stabilizing agent is acetyl tryptophan. The resulting albumin has at least about 80% albumin binding capacity relative to natural plasma albumin, and is storage stable for about 30 months at 30° C.

Abstract: The process is characterised by the preparation of a solution of Von Willebrand Factor or a complex of Factor VIII/Von Willebrand Factor which contains VWF and a concentration of up to 12 IU VWF:RCo/ml and a Von Willebrand Factor/Factor VIII ratio of 0.4 or more; and then proceeding with nanofiltration of the solution prepared in a) through a filter having a pore size of less than 35 nanometres.

Abstract: The therapeutic preparation of FVIIa having a purity of at least 1000 IU/mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography and its subsequent activation.

Abstract: The present invention relates to the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. In particular, the invention relates to methods of treating patients suffering from cognitive disorders, in which the mode of administration of the drug comprises the administration to the patient for a minimum of three successive times of a therapeutically effective amount of human therapeutic albumin by plasma exchange and/or intravenous perfusion, independently of the content of A? in the patient's blood.

Abstract: Apparatus for measuring the optical absorbency of samples of liquids, method and reaction container for its implementation. The apparatus comprises a receiving body for receiving the reaction containers carrying the samples to be analyzed, with means for causing each of the reaction containers to be passed through by a luminous signal of controlled wavelength, having means for conducting it to a scanning head where the luminous signals are picked up by a single CCD sensor, constituting a digital processing system for evaluating the absorbency of the corresponding sample.

Abstract: A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters having a pore size smaller than 35 nm.

Abstract: A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters having a pore size smaller than 35 nm.

Abstract: The invention provides the arrangement of a resilient and flexible tubular element, with shape memory, which contains the product to be metered and which receives an action of limited compression of the walls thereof, in such a way that there is no contact between the internal walls of the opening of the tubular element which propels the product, in such a way that the product supply and discharge are controlled by respective valves situated before and after the compressible tubular metering element.

Abstract: The device comprises a support in the form of a tray or the like, which is at the top and provided inside with first grooves for guiding first cards arranged parallel to each other, forming a single level for the cards and is characterised in that it has sets of grooves interposed between the first grooves, allowing a second level of cards to be placed at a level higher than the first cards.

Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.

Abstract: The device comprises a container with a manually displaceable plunger, the container being extended, forming an integral assembly, on a connection piece and a tubular element which has the filling opening at its end, which tubular element has an intermediate membrane filter for preventing the entry of harmful germs, the device also having anti-tamper security means in the portion disposed between the outlet from the container for the infusion liquid and the filter.

Abstract: The invention is based on feeding the closed bodies to be evaluated to a station for the application of high voltage for the formation of the arc across the inner space of the body and capturing the arc formed by means of a CCD camera which will compare, adjustably, the luminous intensity of the arc created within the body subjected to checking with a threshold value determining whether the luminous intensity is above or below the threshold, which will be the rejection threshold, rejecting the bodies which do not comply with the predetermined threshold value, separating them from the whole of the accepted bodies.

Abstract: A stopper for flasks for pharmaceutical products, characterized in that it comprises, in combination: a plug with resilient means for adjustment to the inner face of the neck and of the mouth of the container and an upper stoppering wall; means for defining a position for pre-stoppering of the flask, before the stoppered position; a protector joined to the plug which comprises a lateral wall of synthetic material, said lateral wall having a projection for engagement with an annular protuberance located on the mouth of the container; the aforesaid protector having an extension which, when the stopper is in its pre-stoppered position, creates a labyrinth closure with respect to the particles which might be present in the surroundings in which the container is being handled.

Abstract: The present invention relates to a new suspension medium or diluent solution for red blood cells for use in haematological methods. The suspension medium or diluent solution for red blood cells may comprise a combination of two or more amino acids of any group, and preserves the red blood cells in the sample for at least 8 weeks.

Abstract: The invention is based on the use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia, comprising the preparation of therapeutic concentrates of alpha-1 antitrypsin, in any form of administration tolerated by humans, the alpha-1 antitrypsin being obtained by purification of human plasma or being produced by recombinant or transgenic technology, with doses equal to or greater than 6 mg of alpha-1 antitrypsin per kg of body weight for a variable period of time.